Oxidized LDL cholesterol is a risk factor for heart disease.
Stratum Nutrition’s (St. Louis) chitin-glucan ingredient Artinia may lower oxidized LDL cholesterol in humans, according to a study published in the European Journal of Clinical Nutrition.
Oxidized LDL cholesterol is cholesterol that has been exposed to high levels of free radicals. Evidence suggests that this form of cholesterol can greatly increase one’s risk of atherosclerotic heart disease.
In a six-week human clinical trial, researchers (including Stratum personnel) assigned 130 human subjects to six weeks of supplementation with Artinia, Artinia and olive oil extract (potentially anti-inflammatory), or placebo. All subjects reported in with borderline or high LDL levels.
At the end of the study, daily Artinia supplementation was deemed effective at lowering oxidized LDL cholesterol over placebo-in a high dose (4.5 g) or a low dose (1.5 g)-but the effect was only significant with the low dose. Artinia didn’t significantly affect HDL cholesterol, triglyceride, insulin or glucose levels in subjects.
Stratum pharmacology manager and coauthor of the study Joseph L Evans, PhD, said the study findings complement previous work performed on animal models.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.